Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.53 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 10/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6172498 | 0.98 | TPMT (0.52) | TPMTHCAR1MLYCDTP53HPGD | |
| SCHEMBL13239446 | 0.93 | TPMT (0.50) | TPMTHCAR1MLYCDTP53HPGD | |
| SCHEMBL14141210 | 0.89 | TP53 (0.50) | TPMTMLYCDTP53HPGDTDP1 | |
| SCHEMBL7115213 | 0.87 | MLYCD (0.43) | TPMTMLYCDTP53HPGDEGFR | |
| SCHEMBL14541116 | 0.86 | MLYCD (0.45) | MLYCDTP53HPGDTDP1EGFR | |
| SCHEMBL3352183 | 0.86 | MLYCD (0.45) | MLYCDTP53HPGDTDP1EGFR | |
| SCHEMBL14376244 | 0.86 | CA12 (0.50) | HCAR1MLYCDTP53HPGDEGFR | |
| SCHEMBL3886133 | 0.86 | MLYCD (0.45) | MLYCDTP53HPGDEGFRERBB2 | |
| SCHEMBL7110187 | 0.85 | MLYCD (0.44) | TPMTMLYCDTP53HPGDEGFR | |
| SCHEMBL3348452 | 0.85 | MLYCD (0.44) | TPMTMLYCDTP53HPGDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534693-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004022523-A2 | 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-9062007-B2 | Cyclic amide BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062007-B2 | Cyclic amide BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | Merck, Sharp & Dohme Corp. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | Merck, Sharp & Dohme Corp. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278334-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | Merck, Sharp & Dohme Corp. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2003002122-A1 | BETA-HYDROXYAMINE DERIVATIVES USEFUL IN TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002100818-A2 | AMINEDIOLS AS AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002094768-A2 | AZA HYDROXYLATED ETHYL AMINE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | TPMT 871/4885HCAR1 38/4885MLYCD 1711/4885 |
| US-20020019403-A1 | Methods to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | TPMT 1971/4885HCAR1 356/4885MLYCD 3082/4885 |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | TPMT 647/4885HCAR1 41/4885MLYCD 1863/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | TPMT 2413/4885HCAR1 137/4885MLYCD 3347/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | TPMT 2177/4885HCAR1 242/4885MLYCD 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.